Subscribe for full access
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Recommendation Rating
1.64
1
2
3
4
5
1 = STRONG BUY | 2 = BUY | 3 = HOLD | 4 = UNDERPERFORM | 5 = SELL
Analysts’ Price Targets
Mean 61.3
Low: 38
High: 77
Total Analysts: 11
Company Profile
DICE Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing oral therapeutics against well-validated targets in immunology. The Company’s platform, DELSCAPE, is designed to discover selective oral small molecules with the potential to modulate protein-protein interactions (PPIs). The Company’s therapeutic candidate, DC-806, is an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17), which is a validated drug target implicated in a variety of immunology indications. The Company is also developing oral therapeutic candidates targeting a4B7 integrin for the treatment of inflammatory bowel disease (IBD) and evaluating oral therapeutic candidates targeting aVB1/aVB6 integrin for the treatment of fibrosis.
We do our best to screen stocks as accurately as possible. Please let us know in the Community if you spot an error or find something questionable. Jazaak Allahu khairan.
